Published in Anaesthesist on July 01, 1996
HAE therapies: past present and future. Allergy Asthma Clin Immunol (2010) 0.98
8 Inhibitors. Transfus Med Hemother (2009) 0.75
The C3-activator system: an alternate pathway of complement activation. J Exp Med (1971) 7.07
C3 proactivator convertase and its mode of action. J Exp Med (1972) 6.94
Lysis of erythrocytes by complement in the absence of antibody. J Exp Med (1970) 3.19
Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system. N Engl J Med (1972) 2.91
The role of properdin in the alternate pathway of complement activation. J Exp Med (1974) 2.77
Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med (1976) 2.66
[Change in therapy target and therapy limitations in intensive care medicine. Position paper of the Ethics Section of the German Interdisciplinary Association for Intensive Care and Emergency Medicine]. Anaesthesist (2013) 2.14
Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function. J Exp Med (1976) 2.13
A molecular concept of the properdin pathway. Proc Natl Acad Sci U S A (1976) 2.09
The alternative pathway of complement activation. Adv Immunol (1976) 1.87
Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus. Immunochemistry (1973) 1.86
The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways. Scand J Immunol (1976) 1.67
Detection of circulating immune complexes in patients with glomerulonephritis. Kidney Int (1977) 1.66
Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation (2001) 1.64
A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement. J Exp Med (1974) 1.63
The induction of macrophage spreading by factor B of the properdin system. J Exp Med (1979) 1.50
Proportional assist versus pressure support ventilation: effects on breathing pattern and respiratory work of patients with chronic obstructive pulmonary disease. Intensive Care Med (1999) 1.50
The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol (2006) 1.50
High-dose intravenous magnesium sulfate in the management of life-threatening status asthmaticus. Intensive Care Med (1993) 1.49
Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active properdin. J Immunol (1977) 1.47
A rational basis for the measurement of free phenytoin concentration in critically ill trauma patients. Ther Drug Monit (1994) 1.45
Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol (1997) 1.41
Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm (1991) 1.41
[Limits of the meaningfulness of intensive care medicine : Position paper of the Ethics Section of DIVI]. Med Klin Intensivmed Notfmed (2016) 1.40
Regulation of macrophage migration by products of the complement system. Proc Natl Acad Sci U S A (1979) 1.29
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia (2006) 1.26
Monitoring perioperative changes in distribution of pulmonary ventilation by functional electrical impedance tomography. Acta Anaesthesiol Scand (1998) 1.26
Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation (1997) 1.23
Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals. Clin Exp Immunol (1991) 1.22
Management of anuric intensive-care patients with arteriovenous hemofiltration. Int J Artif Organs (1980) 1.21
Nephritic factor: its structure and function and its relationship to initiating factor of the alternative pathway. Scand J Immunol (1976) 1.21
Complement utilization by guinea pig 1 and 2-immunoglobulins through the C3 activator system. J Immunol (1971) 1.20
Long-term effects of two different ventilatory modes on oxygenation in acute lung injury. Comparison of airway pressure release ventilation and volume-controlled inverse ratio ventilation. Am J Respir Crit Care Med (1994) 1.17
Release of trapped marker from liposomes by the action of purified complement components. Proc Natl Acad Sci U S A (1969) 1.16
Clustering of ligand on the surface of a particle enhances adhesion to receptor-bearing cells. J Biol Chem (1988) 1.16
Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol (1993) 1.15
Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J Immunol (1995) 1.14
Intensive care training and specialty status in Europe: international comparisons. Task Force on Educational issues of the European Society of Intensive Care Medicine. Intensive Care Med (1998) 1.13
Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int (1997) 1.11
Probing the human receptor for C5a anaphylatoxin with site-directed antibodies. Identification of a potential ligand binding site on the NH2-terminal domain. J Immunol (1993) 1.10
C5a suppresses the production of IL-12 by IFN-gamma-primed and lipopolysaccharide-challenged human monocytes. J Immunol (1999) 1.07
End-expiratory lung impedance change enables bedside monitoring of end-expiratory lung volume change. Intensive Care Med (2002) 1.07
Activated human T lymphocytes express a functional C3a receptor. J Immunol (2000) 1.04
Functions of anaphylatoxin C5a in rat liver: direct and indirect actions on nonparenchymal and parenchymal cells. Int Immunopharmacol (2001) 1.03
Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol (1995) 1.03
Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med (1997) 1.01
Binding of fluorescein-labeled anaphylatoxin C5a to human peripheral blood, spleen, and bone marrow leukocytes. Blood (1992) 1.00
Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol (2000) 1.00
Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies. Eur J Immunol (1996) 1.00
Definitions and methods of cost assessment: an intensivist's guide. ESICM section on health research and outcome working group on cost effectiveness. Intensive Care Med (2002) 0.99
[Prevention of habitual abortion by buffycoat transfusions]. Z Geburtshilfe Perinatol (1986) 0.98
Hydrogen peroxide in expired breath condensate of patients with acute respiratory failure and with ARDS. Intensive Care Med (1993) 0.97
The role of C5a in interleukin-6 production induced by lipopolysaccharide or interleukin-1. Immunology (1991) 0.97
[S3-guideline "Helicobacter pylori and gastroduodenal ulcer disease"]. Z Gastroenterol (2009) 0.96
Human monocyte spreading induced by factor Bb of the alternative pathway of complement activation. A possible role for C5 in monocyte spreading. J Exp Med (1981) 0.96
Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors. Immunology (1994) 0.95
Induction of functional anaphylatoxin C5a receptors on hepatocytes by in vivo treatment of rats with IL-6. J Immunol (2000) 0.95
Anaphylatoxin C3a but not C3a(desArg) is a chemotaxin for the mouse macrophage cell line J774. Eur J Immunol (1998) 0.95
A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artif Organs (1995) 0.95
Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology (1999) 0.95
Anaphylatoxin C5a receptor mRNA is strongly expressed in Kupffer and stellate cells and weakly in sinusoidal endothelial cells but not in hepatocytes of normal rat liver. FEBS Lett (1997) 0.94
The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells. Immunology (2000) 0.94
Multiple organ failure in generalized disseminated tuberculosis. Respir Med (1992) 0.94
Do we need intermediate care units? Intensive Care Med (1999) 0.94
Anaphylatoxin C5a actions in rat liver: synergistic enhancement by C5a of lipopolysaccharide-dependent alpha(2)-macroglobulin gene expression in hepatocytes via IL-6 release from Kupffer cells. J Immunol (2001) 0.93
Severe accidental hypothermia: rewarming strategy using a veno-venous bypass system and a convective air warmer. Intensive Care Med (1999) 0.92
Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis. Eur J Clin Invest (1998) 0.92
Evaluation of respiratory inductive plethysmography in controlled ventilation: measurement of tidal volume and PEEP-induced changes of end-expiratory lung volume. Chest (1998) 0.92
Reversible activation of proactivator (factor B) of the alternative pathway without cleavage of the molecule. Scand J Immunol (1976) 0.92
Burden of illness imposed by severe sepsis in Germany. Eur J Health Econ (2002) 0.92
CD11b and CD11c antigens are rapidly increased on human natural killer cells upon activation. J Immunol (1991) 0.91
Human monocyte spreading induced by factor B of the alternative pathway of complement activation. Cell Immunol (1980) 0.91
Partial lipodystrophy, C3 nephritic factor and clinically inapparent mesangiocapillary glomerulonephritis. Am J Med (1977) 0.91
A novel protein polymorphism of human complement C7 detected by a monoclonal antibody. Immunogenetics (1992) 0.90
CD88 antibodies specifically bind to C5aR on dermal CD117+ and CD14+ cells and react with a desmosomal antigen in human skin. J Immunol (1996) 0.90
[Pyoderma gangrenosum: and important differential diagnosis from wound infection. Case report of a life threatening course]. Anaesthesist (2000) 0.90
C5a receptor and interleukin-6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells. Am J Pathol (1999) 0.89
C7*9, a new frequent C7 allele detected by an allotype-specific monoclonal antibody. Complement Inflamm (1990) 0.89
The human mast cell line HMC-1 expresses C5a receptors and responds to C5a but not to C5a(desArg). Scand J Immunol (1996) 0.88
The biologic role of interleukin-8: functional analysis and expression of CXCR1 and CXCR2 on human eosinophils. Blood (1999) 0.88
A sensitive enzyme immunoassay for the quantitation of human C5a/C5a(desArg) anaphylatoxin using a monoclonal antibody with specificity for a neoepitope. Complement Inflamm (1991) 0.88
[Special respiratory problems in the multiple injured]. Langenbecks Arch Chir (1971) 0.88
Blood dendritic cells carry terminal complement complexes on their cell surface as detected by newly developed neoepitope-specific monoclonal antibodies. Immunology (1991) 0.88
Upregulation of fibronectin but not of entactin, collagen IV and smooth muscle actin by anaphylatoxin C5a in rat hepatic stellate cells. Histol Histopathol (2004) 0.88
Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and factor B. Klin Wochenschr (1988) 0.87
Detection of anaphylatoxin receptors on CD83+ dendritic cells derived from human skin. Immunology (2001) 0.87
Determination of functional residual capacity (FRC) by multibreath nitrogen washout in a lung model and in mechanically ventilated patients. Accuracy depends on continuous dynamic compensation for changes of gas sampling delay time. Intensive Care Med (1998) 0.86
Determination of the epitope specificities of monoclonal antibodies using unprocessed supernatants of hybridoma cultures. J Immunol Methods (1990) 0.86
Elevated plasma levels of the immunosuppressive complement fragment Ba in renal failure. Kidney Int (1991) 0.86
Leucocyte counts and complement activation during pump-driven and arteriovenous haemofiltration. Contrib Nephrol (1983) 0.86
Nephritic factor: Description of a new quantitative assay and findings in glomerulonephritis. Kidney Int (1976) 0.85
Expression and induction of anaphylatoxin C5a receptors in the rat liver. Histol Histopathol (2003) 0.85
Artificially Positive Crossmatches Not Leading to the Refusal of Kidney Donations due to the Usage of Adequate Diagnostic Tools. Case Rep Transplant (2013) 0.85
Quantitation of components of the alternative pathway of complement (APC) by enzyme-linked immunosorbent assays. J Immunol Methods (1990) 0.85